Disease Domain | Count |
---|---|
Neoplasms | 2 |
Infectious Diseases | 1 |
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 4 |
Top 5 Target | Count |
---|---|
HDACs(Histone deacetylase) | 1 |
Target |
Mechanism HDAC inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Oct 2024 |
Sponsor / Collaborator |
Start Date15 Aug 2024 |
Sponsor / Collaborator |
Start Date15 Jul 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
MJ-66 | Glioma More | Preclinical |
CN016 | Chemotherapy-induced damage More | Preclinical |
YCW1 ( HDACs ) | Non-Small Cell Lung Cancer More | Preclinical |
Acnex | Acne Vulgaris More | Discovery |
1J-373 ( FLT3 x c-Kit ) | Acute Myeloid Leukemia More | Pending |